Baiji Shenzhou "Zebutini" pricing outflow: 11300/ box

Introduction: June 12, Baiji Shenzhou Zebutini pricing in China out of the industry: 11300 yuan / box, monthly treatment costs 22,600 yuan, Wen, fengqiuJune 12, Baiji Shenzhou Zebutini pricing in China out of the industry: 11300 yuan / box, monthly treatment costs 22,600 yuanon June 3,, Bazi Shenzhou Zebutinib was approved in China for: 1) treatment of patients with recurrent/incurable (R/R) cell lymphoma (MCL) and 2) treatment of patients with R/R chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)This is the first domestic BTK inhibitor approvedZebutinib for the treatment of MCL's indications has been approved by the FDA for accelerated approval in 2019/11/14, and the product is called BrukinsaAt present, Zebtini's indication has also been submitted in Israel, Zebutini's commercial interest in Israel has been authorized to Medison, which went on sale in the U.Slast year, is priced at $12,935 (120 capsules per bottle) and about 91,472 yuan (120 capsules per bottle) for low-cost entry into the U.SmarketThe first quarter of 2020 disclosed that Zebbutini's u.Ssales were $720,000There are also U.Sinvestment banks that Zebutini's future sales in all areas of indications are expected to reach $836 million, or about 5.858 billion yuanthe world currently has four BTK inhibitors listed in the market of more than $8 billion, but the market share is almost dominated by IbtiniIn August 2017, Ibtini was approved for listing in China at a price of 48,600 yuan per month This was followed by negotiations to enter the 2017 National Health Insurance Category B directory, with a medicare payment standard of 189 yuan (140mg/grain) for the duration of the agreement until December 31, 2020 zebutinib has now completed the milestone of listing in China, the next step is to publish the main data of the SQUOIA clinical trial of Zebutinib compared to phenyartina combined lytoxain for the treatment of primary treatment (TN) CLL or SLL patients as early as the second half of 2020